# Xanthus Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xanthus-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Total disclosed funding: $56M
- Latest round: Series B (Nov 30, 2006)
- Investors on record: 12

## About

Xanthus Pharmaceuticals is a US-based bio pharmaceutical company that operates as a deveeloper of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.

## Funding rounds

- Series B, Nov 30, 2006, $25M — HealthCare Ventures, Oxford Bioscience Partners, Gimv, CDPQ, Still River Funds, NeoMed, CDIB BioScience Venture Management, Yasuda Enterprise Development, GeneChem, Kestrel Ventures, Tekla Capital Management
- Series B, Dec 12, 2003, $31M — HealthCare Ventures, Oxford Bioscience Partners, CDIB Capital Group, Gimv, CDPQ, Still River Funds, CDIB BioScience Venture Management, Yasuda Enterprise Development, GeneChem, Kestrel Ventures, Tekla Capital Management

## Investors

- HealthCare Ventures — Series B
- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series B
- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series B
- Gimv (https://capitalatlas.ai/funds/gimv) — Series B
- CDPQ — Series B
- Still River Funds (https://capitalatlas.ai/funds/still-river-funds) — Series B
- CDIB BioScience Venture Management (https://capitalatlas.ai/funds/cdib-bioscience-venture-management) — Series B
- Yasuda Enterprise Development (https://capitalatlas.ai/funds/yasuda-enterprise-development) — Series B
- GeneChem (https://capitalatlas.ai/funds/genechem) — Series B
- Kestrel Ventures (https://capitalatlas.ai/funds/kestrel-ventures) — Series B
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series B
- NeoMed (https://capitalatlas.ai/funds/neomed) — Series B